MiR-450b-5p enhances the radiosensitivity of HR+ and HER2− breast cancer by targeting CDK6

Ruxing Wu,Hanwang Zhang,Xiaoyuan Huang,Liang Zhuang

DOI: https://doi.org/10.1097/ot9.0000000000000045

2024-06-03

Abstract:Abstract Background The sensitivity of breast cancer cells to radiation is a key cause of locoregional recurrence after postoperative radiotherapy. Several studies have reported that microRNAs (miRNAs) are involved in the radiosensitivity of human breast cancer cells. One miRNA microarray study showed that miR-450b-5p was overexpressed 13.3-fold in patients with estrogen receptor–positive (ER + ) and human epidermal growth factor receptor 2–negative (HER2 − ) breast cancer and no local relapse compared with local relapse patients. However, its underlying mechanism of action remains unknown. Methods The predicted target mRNAs of miR-450b-5p were screened using the TargetScan, miRDB, and miRWalk databases. Western blotting, quantitative polymerase chain reaction, and dual-luciferase reporter assays explored the association between cyclin-dependent kinase 6 (CDK6) and miR-450b-5p. The cell counting kit-8 assay and flow cytometry detected the proliferation of transfected MCF7 cells. Colony formation and xenograft tumors detected the radiosensitivity of the transfected MCF7 cells. Results Bioinformatics analysis, Western blotting, quantitative polymerase chain reaction, and dual-luciferase reporter assays demonstrated that CDK6 was the target gene of miR-450b-5p. Furthermore, in vitro and in vivo experiments showed that miR-450b-5p inhibited MCF7 cell proliferation and cell cycle progression, increased the sensitizer enhancement ratio, and decreased the volume of xenograft tumors after irradiation by regulating CDK6. Conclusions This study demonstrates that miR-450b-5p enhances the radiosensitivity of hormone receptor–positive (HR + ) and HER2 − breast cancer cells and elucidates its mechanism. miR-450b-5p may be considered a therapeutic target in HR + and HER2 − breast cancer treated with radiotherapy.